Merck & Co., Inc. (NYSE:MRK) Stock Price Target Lowered at Royal Bank Of Canada

Merck & Co., Inc. (NYSE:MRK) had its price target decreased by Royal Bank Of Canada from $150.00 to $145.00 in a research note released on Monday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

MRK has been the topic of a number of other research reports. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Bank of America raised their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Jefferies Financial Group boosted their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Argus boosted their price objective on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Finally, Cantor Fitzgerald upped their target price on Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Trading Down 0.1%

Shares of Merck & Co., Inc. stock opened at $145.49 on Monday. The firm has a 50-day simple moving average of $144.25 and a two-hundred day simple moving average of $128.57. The company has a market cap of $358.94 billion, a P/E ratio of 116.39, a price-to-earnings-growth ratio of 6.58 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the company posted $2.13 EPS. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard Deluca sold 11,699 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the transaction, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. This represents a 9.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Abound Financial LLC purchased a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Bullseye Investment Management LLC acquired a new position in Merck & Co., Inc. during the 2nd quarter worth $27,000. Horizons Wealth Management purchased a new stake in Merck & Co., Inc. during the 3rd quarter worth about $30,000. Graney & King LLC increased its holdings in Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the period. Finally, Montgomery Financial Services LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at about $41,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase III results for their personalized mRNA cancer-vaccine program. Reports of a planned U.S.-led, NIH-backed initiative to accelerate personalized cancer-vaccine research could further improve sentiment toward Merck’s vaccine pipeline and partnership prospects. Merck could be below fair value on Phase III cancer vaccine results
• Positive Sentiment: Remigromig achieved the statistical threshold for non-inferiority against Lucentis in diabetic macular edema, and Merck described its safety profile as manageable. The results support potential regulatory discussions for the ophthalmology candidate, although the commercial opportunity remains uncertain. Remigromig late-stage trial data
• Neutral Sentiment: Citigroup raised its Merck price target from $125 to $145 but maintained a Neutral rating, placing its target roughly in line with the prevailing share price. Royal Bank of Canada instead cut its target from $150 to $145 and kept a Sector Perform rating, signaling limited near-term valuation upside. Royal Bank of Canada Merck forecast
• Negative Sentiment: Jefferies reduced its peak-sales forecast for remigromig by 60% after detailed BRUNELLO trial results showed smaller numerical vision improvements than the established rival and raised safety concerns. Although the trial met its non-inferiority endpoint, the weaker efficacy profile could reduce the drug’s eventual market share and valuation contribution. Jefferies cuts remigromig sales forecast

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.